Locally Delivered Therapeutics and Combinations for Expedited Passage of Urinary Stones
Provided are formulations and methods for treating one or more genitourinary conditions. The formulations may include a therapeutic agent that includes a calcium channel blocker, a rho kinase inhibitor, or a combination thereof. The methods may include locally administering a therapeutic agent into a ureter. Systems for delivering a therapeutic agent also are provided.
Researchers
-
formulations, methods, and systems for treating genitourinary conditions
United States of America | Granted | 11,523,985 -
formulations, methods and systems for treating genitourinary conditions
European Patent Convention | Granted | 3,621,606 -
formulations, methods, and systems for treating genitourinary conditions
United States of America | Granted | 12,109,301 -
formulations, methods and systems for treating genitourinary conditions
European Patent Convention | Published application -
formulations, methods and systems for treating genitourinary conditions
Germany | Granted | 3,621,606 -
formulations, methods and systems for treating genitourinary conditions
France | Granted | 3,621,606 -
formulations, methods and systems for treating genitourinary conditions
United Kingdom | Granted | 3,621,606
Publications
Lee, C. X., J. H. Cheah, C. K. Soule, H. Ding, C. A. Whittaker, K. Karhohs, A. A. Burds, K. S. Subramanyam, A. E. Carpenter, B. H. Eisner, and M. J. Cima. "Identification and Local Delivery of Vasodilators for the Reduction of Ureteral Contractions." Nature Biomedical Engineering 4, no. 1 (January 2020): 28–39. https://doi-org.ezproxyberklee.flo.org/10.1038/s41551-019-0482-4.
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.